Anne E. Wojcicki is an American entrepreneur and the co-founder and chief executive officer of the personal genomics company 23andMe. After graduating, Wojcicki worked as a health care consultant at Passport Capital, a San Francisco-based investment fund and at Investor AB. She was a health care investment analyst for 4 years, overseeing health care investments, focusing on biotechnology companies. Disillusioned by the culture of Wall Street and its attitude towards health care, she quit in 2000, intending to take the MCAT and enroll in medical school. Instead, she decided to focus on research. In 2006, she co-founded 23andMe with Linda Avey. 23andMe is a privately held personal genomics and biotechnology company, based in Mountain View, California, that provides genetic testing. The company is named for the 23 pairs of chromosomes in a normal human cell. The company's personal genome test kit was named "Invention of the Year" by Time magazine in 2008. From 2015, the FDA started to give approval to 23andMe's health-related tests, including risk from cystic fibrosis, sickle cell anemia, certain cancers, Alzheimer's, Parkinson's, and coeliac disease. In 2018, 23andMe entered into a four-year collaboration with GlaxoSmithKline to develop new medicines. Wojcicki is also a member of the Xconomists, an ad hoc team of editorial advisors for the tech news and media company, Xconomy. In October 2013, Fast Company named Wojcicki "The Most Daring CEO". She is a co-founder and board member of the Breakthrough Prize.